Literature DB >> 14764706

Conformation and glycosylation of a megalin fragment correlate with nephritogenicity in Heymann nephritis.

Alfonso Tramontano1, Sudesh P Makker.   

Abstract

Active Heymann nephritis (AHN), a rat model of autoimmune glomerulonephritis, is induced by immunization with autologous megalin, a 600-kDa cell surface glycoprotein isolated from crude renal extracts. Recombinant proteins containing a 563-residue N-terminal sequence of megalin were obtained from Escherichia coli and baculovirus-insect cell expression systems. Rats immunized with the soluble, secreted protein encoded by a baculovirus construct elicited high titer anti-megalin autoantibodies and developed glomerular immune deposits and elevated proteinuria consistent with AHN. Rats treated with the bacterial or nonsecreted insect cell proteins produced a milder anti-megalin response and did not develop the disease. Nephritogenicity appeared to correlate with conformational or other structural features of native megalin. All three recombinant proteins were reactive in Western blots with rabbit anti-megalin antiserum, whereas the insect cell-derived proteins reacted preferentially in Western blot and ELISA with anti-megalin autoantibodies from rats with AHN induced by native megalin. Only the secreted insect cell product was stained in a lectin blot, suggesting its specific glycosylation. These observations provide evidence that a megalin N-terminal domain includes B and T cell epitopes sufficient for a pathogenic autoimmune response and that a native-like conformation and glycosylation are essential for the induction of disease. The importance of conformational B cell epitopes for pathogenic autoantibodies recapitulates observations made in other models of organ-specific autoimmune disease. Glycosidic modifications could influence the presentation of either B or T cell epitopes in AHN, consistent with emerging evidence of the role of post-translational modifications in pathogenic autoimmune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764706     DOI: 10.4049/jimmunol.172.4.2367

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Idiopathic membranous nephropathy: an autoimmune disease.

Authors:  Sudesh P Makker; Alfonso Tramontano
Journal:  Semin Nephrol       Date:  2011-07       Impact factor: 5.299

Review 2.  Pathogenesis of membranous nephropathy: recent advances and future challenges.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Nat Rev Nephrol       Date:  2012-02-28       Impact factor: 28.314

Review 3.  A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Pflugers Arch       Date:  2017-06-08       Impact factor: 3.657

4.  posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.

Authors:  Birgitte Giersing; Kazutoyo Miura; Richard Shimp; Jin Wang; Hong Zhou; Andrew Orcutt; Anthony Stowers; Allan Saul; Louis H Miller; Carole Long; Sanjay Singh
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 5.  Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.

Authors:  P Ronco; H Debiec
Journal:  Semin Immunopathol       Date:  2007-09-26       Impact factor: 9.623

6.  Mass Spectral Detection of Forward- and Reverse-Hydrogen/Deuterium Exchange Resulting from Residual Solvent Vapors in Electrospray Sources.

Authors:  H Jamie Kim; O Tara Liyanage; Marina R Mulenos; Elyssia S Gallagher
Journal:  J Am Soc Mass Spectrom       Date:  2018-07-11       Impact factor: 3.109

Review 7.  Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role.

Authors:  Wenbin Liu; Chang Gao; Haoran Dai; Yang Zheng; Zhaocheng Dong; Yu Gao; Fei Liu; Zihan Zhang; Zhiyuan Liu; Weijing Liu; Baoli Liu; Qingquan Liu; Jialan Shi
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.